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The human PrP gene (PRNP) has two common alleles that encode either 
methionine or valine at codon 129. This polymorphism modulates disease 
susceptibility and phenotype of human transmissible spongiform 
encyphalopathies (TSEs) but the molecular mechanism by which these effects 
are mediated remains unclear. Here, we compared the misfolding pathway that 
leads to the formation of β-sheet-rich oligomeric isoforms of the methionine 129 
variant of PrP to that of the valine 129 variant. We provide evidence for 
differences in the folding behaviour between the two variants at the early stages 
of oligomer formation. We show that Met129 has a higher propensity to form β-10 
sheet-rich oligomers whereas Val129 has a higher tendency to fold into α-helical-
rich monomers. An equimolar mixture of both variants displayed an intermidate 
folding behaviour. We show that the oligomers of both variants are initially a 
mixture of α-rich and β-rich conformers that evolve with time to an increasingly 
homogeneous β-rich form. This maturation process, which involves no further 
change in proteinase-K resistance, occurs more rapidly in the Met129 form than 
the Val129 form. Although the involvement of such β-rich oligomers in prion 
pathogenesis is speculative, the misfolding behaviour could, in part, explain the 
higher susceptibility of individuals that are methionine homozygote to both 
sporadic and variant CJD. 20 
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INTRODUCTION 
The transmissible spongiform encephalopathies (TSEs) are a group of fatal, 
neurodegenerative disorders that affect humans and animals and are believed to be 
caused by a novel class of infectious pathogen, the prion (1,2). These diseases have 
attracted considerable interest not only because of their unique biology but also 
because of the appearance of new variant of Creutzfeldt-Jakob disease (vCJD) (3), 
which appears to be caused by dietary exposure to the causative agent of bovine 
spongiform encephalopathy (BSE) (4,5). At the heart of disease pathogenesis lies a 
poorly understood structural rearrangement of PrP, a host-encoded glycoprotein of the 
nervous and lymphoid systems. The normal cellular form of the prion protein (PrPC) 10 
undergoes a conversion that leads to the accumulation of an abnormal, 
conformationally-altered isoform (PrPSc). According to the “protein-only” hypothesis 
of prion propagation, PrPSc is the principal or sole component of transmissible prions 
(6). PrPSc differs from PrPC by increased β-sheet content, increased resistance to 
proteinase K and an oligomeric rather than a monomeric state (7). 
 
The human PrP gene (PRNP) exists in two major allelic forms that encode either 
methionine or valine at codon 129, with allele frequencies of 0.63 and 0.37 in western 
European and American populations, respectively (8,9). This polymorphism is a key 
determinant of susceptibility to sporadic (10) and acquired (8,11) prion diseases and 20 
may affect age at onset (12-14). Based on the analysis of 300 sporadic CJD subjects, 
Parchi et al. identified six distinct clinicopathological variants of sCJD, which 
appeared to be specified largely by the genotype at codon 129 and the physiochemical 
properties of PrPSc (14). More recently, an extensive analysis, which included the 
metal ion-dependent conformation of PrPSc, of a large number of sCJD cases showed 
that PrPSc types are associated with the residue encoded at codon 129, the duration of 
illness and with neuropathological phenotype (15). PrPSc types 1 and 4 have so far 
been detected only in Met129 homozygotes, type 4 being uniquely associated with 
vCJD, type 3 in cases containing a Val129 allele and type 2 in any PRNP codon 129 
genotype (16). The codon 129 polymorphism seemed to modulate the pattern of 30 
neuropathology and the extent of lesions in sCJD, as shown in a study that involved 
70 patients who died in France between 1994 and 1998 (17). Codon 129 
polymorphism also has epistatic effects on the phenotypic effects of mutations 
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elsewhere in the prion gene. For example, the Asp178Gln mutation combined with a 
methionine at position 129 results in fatal familial insomnia (FFI) (18). In contrast, 
the same mutation with a valine encoded at position 129 results in familial CJD (19). 
Similarly, Val129 homozygotes in association with the Phe198Ser mutation 
predispose patients to the Indiana kindred variant of Gerstmann-Straussler-Scheinker 
(GSS) disease (20). Furthermore, an increased prevalence of genotype Val/Val at the 
polymorphic site 129 has been described in patient with early onset Alzheimer’s 
disease (21) and a shift in cognitive decline towards early age in carriers of PRNP129 
Val/Val has recently been reported (22). 
 10 
Despite the clear importance of the polymorphism at codon 129 in the PRNP gene and 
its link to disease susceptibility and pathogenesis, the molecular mechanisms by 
which these effects are mediated remain unclear. The in vitro, thermodynamic 
stability of recombinant PrP is not affected by the Met129Val mutation or by other 
substitutions related to inherited human prion diseases (23). Structural studies, 
however, have shown evidence for hydrogen bonding between residues 128 and 178, 
which might provide a structural basis for the highly specific influence of 
polymorphism in position 129 on disease phenotype that segregates with Asp178Gln 
(24). Molecular dynamic simulations of low pH-induced conformational conversion 
of PrP has provided further clues as to the role of residue 129 (25). In these 20 
simulations, Met129 seems to interact with Val122 leading to the recruitment of more 
N-proximal residues into an expanding β-sheet. As a complementary approach, we 
have chosen to study the folding properties of the two PrP allelomorphs 
experimentally, by examining the misfolding pathway that leads to the formation of 
β-sheet-rich oligomeric isoforms (26). We show that PrP-Met129 has a higher 
propensity to form β-sheet-rich oligomers whereas PrP-Val129 has a higher tendency 
to fold into α-helical-rich monomers. We also provide evidence that the dynamics of 
maturation of the oligomers differ between the two variants. The maturation process 
occurs over time at the expense of the α-helical-like monomers at a faster rate for 
PrP-Met129 than for PrP-Val129. Once the oligomers from either allelomorph have 30 
been formed they show similar proteinase K resistance that does not change 
throughout the oligomer maturation process. The observed differences in the 
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misfolding of PrP-Met129 and PrP-Val129 could explain the high susceptibility of 
individuals that are methionine homozygote to sporadic as well as variant CJD.  
 
MATERIALS AND METHODS 
Cloning of PrP genes and protein purification. Genomic DNA encoding 
methionine/valine at codon 129 of PRNP gene (18) was extracted from the blood of a 
heterozygote individual using standard phenol-chloroform methods. The fragment of 
the PRNP gene spanning codon 90 through 231 was amplified with the 
oligonucleotide primers 5′-cgggatcccatgcaaggaggtggcacccacagtcagtggaacaagccg-3′ 
and 5′-cccaagcttcatgctcgatcctctctggtaataggcctgag-3′ in 100 µl PCR buffer that 10 
contained 300 ng of each DNA, 2 units Taq DNA polymerase, 200 µM of each dNTP, 
0.2 µM of each primer, 3.5 µM MgCl2, 10 mM Tris-HCl pH 9.0, 0.1 % Triton X-100, 
50 mM KCl. The following PCR conditions were used: an initial denaturation (95°C, 
3 min) followed by 25 cycles of denaturation (95°C, 1 min), annealing (55°C, 1 min), 
extension (72°C, 1 min), and a final elongation (72 °C, 8 min). Restriction sites 
BamHI and HindIII, including extra-nucleotides for efficient cleavage close to the 
ends, were introduced in the primers. The PCR fragment was cloned into the 
pTrcHis2B vector that incorporated a C-terminal His-tag (Invitrogen life technologies, 
Paisley, UK) according to the manufacturer’s instructions. The identity of human PrP 
clones was confirmed by sequencing with the BigDye Terminator v3.0 on ABI-Prism 20 
3100 Genetic Analyzer (Applied Biosystems). The clones corresponding to PrP90-231 
with Met129 or Val129 were identified by comparison with human PrP clones 
available in the databases (Accession numbers: M13667, P04156). Escherchia coli 
expression and purification of recombinant human PrP was performed as previously 
described (27) except that the buffer used to solubilise inclusion bodies did not 
contain DTT. Stocks of highly purified proteins were stored in 6 M guanidine 
hydrochloride, 50 mM Tris-HCl pH 7.2. 
 
Oligomer formation by HPLC-gel filtration and dialysis methods. Rapid refolding 
of proteins into oligomeric isoforms was carried out at concentrations of 10 mg/ml 30 
and 30 mg/ml. PrP- Met129 and PrP-Val129 were denatured in 6 M guanidine 
hydrochloride, 50 mM Tris-HCl pH 7.2 and were injected (100 µl) onto a size 
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exclusion chromatography (SEC) column (TSK-Gel SWXL G3000 HPLC column, 
7.8 x 300 mm, Phenomenex, Macclesfield, UK), equilibrated in 20 mM sodium 
acetate, 0.2 M NaCl, pH 3.7, 1 M urea and 0.02% sodium azide (26). This rapid 
oligomer formation on SEC-HPLC corresponded to time zero as opposed to time 
course analysis of oligomer formation during dialysis. This time course analysis of 
oligomer formation was carried out as follows: 1 ml of 6M guanidine-hydrochloride-
denatured proteins (10 mg/ml or 30 mg/ml), was dialysed at room temperature against 
2 litres of 20 mM sodium acetate, 0.2 M NaCl, pH 3.7, 2 M urea by use of a Slide-A-
Lyser dialysis cassette (Perbio Science UK Ltd, Tattenhall, UK) of 10 kDa cut off. 
Aliquots were withdrawn, after carefully shaking the cassette to ensure homogeneity, 10 
after 30 min, 2, 4 and 24 hours and analyzed by SEC as described above. Protein 
peaks were manually collected for subsequent analysis. Circular dichroism was 
carried as previously described (28) to assess the secondary structure of the protein.  
 
Analytical Reversed-phase HPLC. Protein fractions collected during SEC analysis 
were kept in SEC elution buffer at room temperature and analyzed after 2, 12, 30, 
110, 140, 200 and 300 days by analytical reversed-phase (RP) HPLC (Sephasil C4, 5 
µm, 4.6 x 250 mm) (Amersham Biosciences, Little Chalfont, UK). Proteins were 
eluted with a linear gradient of H2O + 0.1% TFA to 95 % acetonitrile + 0.09% TFA 
over 25 minutes.  20 
 
All HPLC separations were performed at room temperature with a flow rate of 1 
ml/min by means of a Perkin-Elmer HPLC system composed of a Binary LC pump 
250 and a Diode array detector 235C controlled by Total Chrome software version 6.2 
(Perkin-Elmer, Seer Green, UK), through a PE Nelson 600 series link. The eluent was 
monitored by UV absorption at 280 nm. 
 
Proteinase K digestion. Recombinant human PrP collected from SEC-HPLC was 
subjected to proteinase K digestion after 2, 12 and 140 days maturation of the 
oligomers. The solution was incubated at 37 °C with a ratio of 1: 24 PK to protein in 30 
20 mM sodium acetate, 0.2 M NaCl, pH 5.5. Aliquots of the digests were taken after 
15, 30 and 60 minutes and snap frozen for analysis by SDS-PAGE and mass 
spectrometry. 
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On line capillary HPLC nanospray mass spectrometry. Mass spectrometry was 
carried out on a Quattro II tandem quadrupole mass spectrometer (Micromass UK 
Ltd, Altrincham, UK) equipped with on-line capillary HPLC as detailed in (29). 
Briefly, the capillary HPLC was 180 µm i.d. and was packed with 3.5 µm Jupiter C18 
resin (Phenomenex, Macclesfield, UK). A flow rate of 1 µl/min was used and proteins 
were eluted with a gradient from 0-70% solvent A to B, where solvent A was 95:5 
water:acetonitrile with 0.05% trifluoroacetic acid and solvent B was 95:5 
water:acetonitrile with 0.05% trifluoroacetic acid. The eluent was passed directly to 
the mass spectrometer which was operated in continuous flow nanospray mode. Full 
scan mass spectra (m/z 300-2100) were acquired every 5 seconds. 10 
 
RESULTS 
Characterization of recombinant human PrP-Met129 and PrP-Val129 
Recombinant human prion protein variants, HuPrP90-231 Met129 and HuPrP90-231 
Val129, were purified to homogeneity by immobilized-metal affinity chromatography 
(see supplementary figure 1) followed by RP-HPLC. Purified proteins were analysed 
by mass spectrometry to confirm purity and identity. Omitting DTT from the buffer 
used to solubilize the inclusion bodies and allowing disulfide bond to form in the 
oxidizing environment of the IMAC was found to yield a fully oxidized protein (see 
supplementary figure 1) that has characteristics of PrPC, such as a monomeric state, 20 
high α-helical content and proteinase K sensitivity. All the studies presented in this 
paper were performed on proteins that included a C-terminal His-tag. 
 
PrP-Met129 has an intrinsically higher propensity to oligomerize than PrP-
Val129  
To assess the effect of the codon 129 polymorphic residue on the formation of non-
native isoforms, both protein variants were denatured in 6 M guanidine hydrochloride, 
50 mM Tris-HCl pH 7.2, and allowed to fold under conditions favouring the 
formation of β-oligomer species (26). To dissect the in vitro folding pathway of prion 
protein misfolding we used size exclusion chromatography (SEC), dialysis and 30 
circular dichroism (CD). The denatured proteins (30 mg/ml) were injected onto a SEC 
column that had previously been equilibrated in 20 mM sodium acetate, 0.2 M NaCl, 
pH 3.7, 1 M urea and 0.02% sodium azide and eluted with the same buffer. The 
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elution profile of the Met129 variant shows two major peaks and one minor peak (Fig. 
1A). Peak I (terminology as given by Baskakov et al (26)) eluted at 5.68 min and 
corresponded to high molecular weight aggregates (Fig. 1A). Peak II eluted at 6.54 
min and corresponded to the oligomeric isoform while peak III, which eluted at 9.08 
min, had a similar retention time to monomeric protein (Fig. 1A). The elution profile 
of Val129 variant shows the same three peaks but in different proportions, with peak 
II eluting as a shoulder to peak I (Fig. 1B). In order to mimic a heterozygote situation 
of an individual that carries both alleles we have analyzed the folding behaviour in a 
1:1 mixture of Met129 and Val129 (Fig 1C). The elution profile of the equimolar 
mixture showed three peaks as seen before (Fig 1C). Integration of the peaks in figure 10 
1A and 1B revealed that less than 2% of the Val129 variant had formed oligomers 
under these rapid refolding conditions (within the first 10 minutes of the SEC-elution) 
as compared to more than 70% in the case of Met129 (Fig. 1D). In addition, the 
percentage of monomeric population that was formed within 10 minutes was 
calculated to be about 66% for the Val129 variant but only 24% for the Met129 
variant (Fig. 1D). Integration of the peaks in the equimolar mixture showed that the 
percentage of oligomeric form was reduced to about 44%, corresponding to 
approximately 30% reduction in the amount of oligomers as compared to the situation 
of the Met129 alone (Fig. 1D). Also the amount of the monomeric population in the 
mixture 1:1 increased by about 17% when compared to that of the Met129 alone (Fig. 20 
1D). The monomeric forms of Met129 and Val129 variants yielded CD spectra with 
two minima at 208 nm and 222 nm, indicative of a predominantly α-helical 
conformation (data not shown). The CD spectra of protein from peak II of PrP-
Met129 and peaks I and II of PrP-Val129 did not give clear information about the 
protein conformations, but suggested that these fractions were composed of a mixture 
of α-helical and β-sheet forms.  
 
To investigate the formation and evolution of the oligomers that eluted in peak II in 
more detail, we used a slower dialysis method of refolding that allowed analysis at 
different times after initiation of the refolding. Two protein concentrations, 30 and 10 30 
mg/ml, were analyzed in parallel. The composition of the dialysis buffer was the same 
as that used in SEC elution buffer, except that, to maximize the formation of 
oligomers, the urea concentration was increased to 2 M (28). After 30 minutes 
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refolding, and at 30 mg/ml, both allelomorphs adopted predominately oligomeric 
forms (peak II) with virtually no monomeric protein present (peak III); this elution 
profile did not change over the course of the experiment (Fig. 2A). Similar results 
where obtained with a mixture (1:1) of Met129 and Val129 (data not shown). The CD 
spectra of oligomers collected at 30 min and 1 h showed that the population was not 
dominated by β-sheet rich structures but contained some α-helical rich protein (Fig. 
2, C-D). However, by four hours the CD spectra of the protein contained in peak II 
from both allelomorphs were typical of proteins possessing high amounts of β-sheet 
and the spectra remained constant thereafter.  
 10 
In contrast, at 10 mg/ml (Fig. 2B) the kinetics of oligomerization of PrP-Met129 were 
significantly different from those of the PrP-Val129. The disappearance of aggregated 
proteins from peak (I) occurred more rapidly in the Met129 variant than in the Val129 
variant, which suggests that, under oligomer-promoting conditions, the aggregated 
material from PrP-Met129 has a higher propensity to convert into oligomer than 
aggregated protein from PrP-Val129. To test this, we took aggregated proteins from 
peak (I) of PrP-Met129 and PP-Val129 from SEC at time zero and monitored their 
evolution over time by re-injecting them onto the same SEC. Time course comparison 
between the two allelomorphes clearly demonstrated the higher propensity of the 
Met129 variant to oligomerize than the Val129 variant (see supplementary figure 2). 20 
Virtually all aggregated PrP-Met129 converted into oligomeric isoforms over a period 
of 12 days, whereas a substantial amount of PrP-Val129 remained as aggregates. To 
investigate the behaviour of monomeric species in peak III under the same 
oligomeric-promoting conditions we compared the rate of oligomerization of the 
Met129 variant to that of the Val129 variant collected from SEC at time zero. Time 
course comparison between the two allelomorphs clearly revealed that monomeric 
Met129 has a higher propensity to oligomerize than monomeric Val129. This 
difference in oligomerization rates was apparent after two days of incubation at room 
temperature (see supplementary figure 2). 
 30 
From these data we conclude that, under these conditions, the Met129 variant has an 
intrinsically higher propensity to form oligomer isoforms than the Val129. The high 
oligomerization propensity of the methionine variant becomes even more apparent 
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under the highest protein concentration and rapid refolding conditions. Since this is 
true for denatured, aggregated or natively-folded monomeric protein, the higher 
propensity of oligomerisation is clearly independent of the starting state of the 
protein. 
 
The oligomers of both Met129 and Val129 variants are conformationally 
heterogeneous and show different kinetics of maturation 
It has been shown that the oligomeric isoforms of mouse and Syrian hamster PrP are 
formed of populations of structurally heterogeneous proteins (26). RP-HPLC analysis 
showed that reduced forms of recombinant mouse PrP existed in multiple β-sheet rich 10 
isoforms with distinct retention times (30,31). Accordingly, we used RP-HPLC to 
investigate the effect of the residue encoded at codon 129 on the composition of the 
oligomer population that eluted from SEC in peak II. Aliquots of this fraction were 
incubated at room temperature in SEC elution buffer (20 mM sodium acetate, 0.2 M 
NaCl, pH 3.7, 1 M urea and 0.02% sodium azide) and analyzed at various times (Fig. 
3). After two days incubation, the RP chromatogram of PrP-Met129 showed two 
peaks with distinct retention times (Fig. 3A), however for PrP-Val129 only one major 
peak was observed (Fig. 3B). A second peak could be seen only after 12 days 
incubation. The two peaks were designated (IIa) and (IIb), with shorter and longer 
retention times, respectively. In order to rule out the possibility that the two peaks 20 
represented unexpected modification to the proteins, we analysed them by mass 
spectrometry (Fig. 4). The deconvoluted mass spectra of PrP-Met129 IIa and PrP-
Met129 IIb demonstrate that they represent proteins of the same molecular mass (Fig. 
4, A-B). Similarly, the deconvoluted mass spectra of PrP-Val129 IIa and PrP-Val129 
IIb showed that they also represented proteins with similar molecular masses (Fig. 4, 
C-D). From these analyses we infer that no covalent differences are evident and that 
the two peaks observed by RP-HPLC represent different conformations, with different 
amounts of hydrophobic residues exposed at the protein surface. 
 
Two important observations can be clearly made from RP-C4 chromatograms. Firstly, 30 
the proportions of the two forms of PrP-Met129 and PrP-Val129 were different; the 
proportion of protein eluting in peak (IIa) was higher for PrP-Met129 after 12 days 
incubation (Fig. 3, A vs. B), while for PrP-Val129 there was more protein that eluted 
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in peak (IIb). Secondly, the proportions of the two peaks changed over time at 
different rates for Met129 and Val129 variants. In particular, the proportion of protein 
eluting in peak (IIb) decreased at a higher rate in the oligomer of PrP-Met129 (Fig. 
3A) than in the oligomer of PrP-Val129 (Fig. 3B). The peak (IIb) of the oligomer from 
both allelomorphs seemed to have a retention time similar to that of the corresponding 
α-helical monomers. Because RP-HPLC uses differences in the hydrophobic 
properties to achieve separation between bio-molecules, it can be concluded that the 
protein population present in the highly retained peak (IIb) has more surface-exposed 
hydrophobic residues than the protein population present in peak IIa. Furthermore, the 
protein population present in peak (IIb) appears to undergo conversion to become 10 
recruited into the population that eluted in peak (IIa). Over time, this conversion 
seemed to occur much quicker with PrP-Met129 than with PrP-Val129 (Fig. 3, A vs. 
B). 
 
Because of the long storage time of both allelomorphs in SEC elution buffer at room 
temperature, we have used mass spectrometry to assess the integrity of the samples 
(see supplementary figure 3). After 2 and 12 days of oligomerization, both 
allelomorphs had molecular masses that matched those predicted from the amino acid 
sequences. However, after 30 days of oligomerization, the deconvoluted mass spectra 
of both variants showed an additional species with a molecular mass that 20 
corresponded to the cleavage of the N-terminal two residues from the proteins (see 
supplementary figure 3). The two variants showed the same level of cleavage that 
increased over time to yield, 300 days later, proteins that were completely lacking two 
residues from the N-terminus (see supplementary figure 3). The cleavage occurred in 
the peptide bond linking an aspartyl residue to a prolyl residue (Fig. 5F). The lability 
of Asp-Pro bonds under acidic conditions has previously been reported (32) and 
provides a simple explanation for our observation. The cleavage occurred at the same 
rate for both Met129 and Val129 variants and at a region of the N-terminal that was 
PK sensitive (see below) and, therefore, was unlikely to impact the differences that 
were observed during oligomerization of the two allelomorphs. 30 
 
The oligomers of Met129 and Val129 show similar proteinase K resistance 
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Limited PK digestion has been used widely to distinguish the disease isoform, PrPSc, 
from PrPC as well as to probe differences between PrPSc strains (33,34). We therefore 
used limited PK digestion in combination with on-line capillary HPLC mass 
spectrometry to probe differences between Met129 and Val129 variants during 
oligomerization. After treatment for up to 60 min with a 1:24 ratio of PK to protein, 
capillary HPLC_MS demonstrated that digestion of the oligomers from both 
allelomorphs yielded a range of short peptides that eluted before 20 min (insets in Fig. 
5, A-B) that were liberated from the N-terminal and C-terminal His-tag regions of the 
protein. The central and C-terminal domains remained intact and eluted after 20 min 
as two peaks from the reversed phase column (insets in Fig. 5, A-B). These 10 
polypeptides separated into two peaks that started either from residues 117 or 135 
respectively, as a result of differential cleavage within the hydrophobic region (Fig. 
5F). Comparison of deconvoluted mass spectra of polypeptides starting at 117 
between PrP-Met129 (Fig. 5A) and PrP-Val129 (Fig. 5B) oligomers, showed three 
major PK-resistant cores with matching cleavage sites for each variant. The 
differences in masses (32 Da) between these PK-resistant fragments were due only to 
the presence of methionine or valine at position 129. Similarly, the comparison of 
deconvoluted mass spectra of polypeptides that started at 135 between PrP-Met129 
(Fig. 5C) and PrP-Val129 (Fig. 5D) oligomers, revealed four major PK-resistant 
polypeptides with identical molecular masses for Met129 and Val129. Most, if not all, 20 
of the C-terminal His-tag remained PK-sensitive (Fig. 5F) during oligomerization, 
indicating that it was unlikely to interfere with the oligomerisation process. SDS-
PAGE separation of the PK digests at various times of oligomerization (Fig. 5E) 
provided additional evidence that oligomers from PrP-Met129 and PrP-Val129 have 
similar PK-resistant properties. 
 
DISCUSSION 
In this work we show that the polymorphism at codon 129 affects the kinetics of 
oligomerization that leads to non-native isoforms of human prion protein. Starting 
from an unfolded state and when forced rapidly to adopt the oligomeric form under 30 
low pH and at high protein concentration, the Met129 variant clearly exhibited a 
preference for the oligomeric state, whereas Val129 variant favoured the α-helical-
rich, monomeric state. We have ruled out the possibility that the denatured starting 
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protein contained any oligomeric forms of PrP by SEC analysis under denaturing 
conditions using 6M guanidine hydrochloride, 50 mM Tris-HCl pH 7.2 as elution 
buffer. Indeed the chromatograms showed only monomeric population of both PrP 
variants (see supplementary figure 4). How then does residue129 influence this 
folding behaviour? The first clue can be derived from the solution structure of human 
PrP determined by NMR (35). Residue 129 lies within the first β-strand (residues 
128-131) in human PrP. Riek et al (36) proposed that this short β-sheet might be a 
‘nucleation site’ for a conformational transition from PrPC to PrPSc that could include 
the loops connecting the β-sheet to the first helix. Prion peptide models have also 
indicated the possible involvement of the region containing the first β-strand in the 10 
conformational switch of PrP (37,38).To our knowledge there is no published 
structure of Val129 variant of human PrP, however, molecular dynamic simulations 
of Syrian hamster PrP90-231 at neutral pH showed that when a valine residue was 
present at position 129 instead of a methionine residue, the proportion of protein with 
three-stranded, antiparallel β-sheet structure increased from 0% to 23% (39). The 
three β-strands spanned residues 115-116, 119-122 and 129-130 without affecting the 
thermodynamic stability of PrP, as was demonstrated experimentally (23). Molecular 
dynamic simulations of Syrian hamster PrP109-219 at low pH revealed that regions 
around β-strand 1 and β-strand 2 were potential sites for conversion to β-structures 
(25). In particular, the first β-strand served as a structural nucleus for the formation of 20 
new, and propagation of existing, β-like structure (25). The interactions between 
Met129 and Val122 and between Tyr128 and Tyr162 illustrated the role of tertiary 
interactions between side chains nucleating secondary structure formation, as has 
been observed for helix formation in barnase (40). 
 
Our experimental data show that, under conditions that favour rapid formation of 
oligomers, SEC can be used to partition protein folded into aggregated, monomeric 
and oligomeric states so that differences in folding of Met129 and Val129 variants 
become clear. It has been shown that folding of recombinant, murine prion protein 
into α-helix rich conformation is extremely rapid (41) and is under kinetic control 30 
(28). We show in this work that the propensity of recombinant human prion protein to 
fold into monomeric α-helical-rich population is increased when residue 129 was 
occupied by a valine. However, when the same position is occupied by methionine a 
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tendency for oligomerization can be observed, with comparatively little monomeric 
α-helical-rich population. These differences in folding behaviour can be explained by 
a fundamental event in protein folding, which is driven by a small number of specific 
residues involved in the formation of a well-defined, specific nucleus that then allows 
the rest of the structure to coalesce efficiently around it (42,43). The high β-sheet 
propensity of valine residues as compared to methionine residues (44,45) makes PrP 
in which valine is present at residue 129 more favourable to adopt the native local β-
sheet that would temporarily stabilize the Val129 allelomorph in the monomeric α-
helical PrP. 
 10 
Differences between the oligomers formed from Met129 and Val129 could be seen 
when we explored the hydrophobicity of the oligomers as they evolved over time. 
These differences were consistent with early events that were observed during the 
rapid misfolding process. That is, the proportion of oligomer subunits with 
hydrophobic properties resembling those of the α-monomer was higher in PrP-Val129 
than in the PrP-Met129. Over the course of several weeks of incubation, the 
oligomerization process in both variants occurred at the expense of the α-helical-like 
population that became a substrate for oligomer recruitment (28,46). The presence of 
the α-helical-like species in the oligomer reflected the heterogeneous nature of this 
non-native form of PrP. This finding was consistent with the previously published 20 
supra molecular electrospray ionisation mass spectrometry results (26). On the basis 
of these observations we propose a model (Fig. 6) that depicts the formation of non-
native β-oligomers in vitro. Under appropriate conditions (low pH and high protein 
concentration) the acquisition of this non-native form can happen from either 
denatured, aggregated or native forms and involves two steps: a rapid oligomerization 
phase followed by a slow maturation phase characterized by a structural 
rearrangement of the oligomers. The presence of a methionine at codon 129 affects 
both the kinetics of oligomerization and those of the maturation phase.  
 
A hallmark of the disease isoform, PrPSc, is its partial resistance to proteinase K 30 
digestion compared to normal cellular PrP. This property has also been used to probe 
differences between PrPSc conformations. We found that once oligomers from both 
allelomorphs are formed they show similar proteinase K resistance that does not 
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change throughout the oligomer maturation process. This indicates that if one relies 
solely on PK digestion to investigate PrP conformations, one could miss the detection 
of dynamic conformational changes influenced by the polymorphism at codon 129 in 
human PrP during disease pathogenesis.  
 
It has been reported that two mutations in α-synuclein that are linked to early-onset 
Parkinson’s disease can accelerate the oligomerization but not fibrilization suggesting 
that formation of nonfibrillar oligomer is likely to be critical in disease pathogenesis 
(47). There is no evidence so far that these β-oligomers exist in vivo or can directly 
cause prion diseases either alone or with the help of other factors. The high affinity 10 
and newly reported ligands that we have isolated in our laboratory (48,49) would help 
investigating the presence in vivo of the β-oligomers. The observed differences in the 
misfolding behaviour between Met129 and Val129 variants could provide a kinetic 
explanation to the observed high susceptibility of individuals that are methionine 
homozygote to sporadic as well as to variant CJD. Attempt to model a heterozygote 
situation by mixing Met129/Val129 (1:1) and allowing the rapid refolding to occur 
has yielded some promising results in that the amount of oligomers formed was 
reduced by approximately 30% as compared to the homozoygote-like situation in the 
Met129 alone, indicating certain degree of inhibition of the oligomerization in the 
heterozygote. 20 
Phylogenetically, methionine is the ancestral amino acid at codon 129 (50), and 
Val129 is a mutation found in humans. Worldwide PRNP haplotype diversity and 
coding allele frequencies suggest that strong balancing selection at this locus occurred 
during the evolution of modern human and made heterozygosity at PRNP a significant 
selective advantage (51). Our data could provide a mechanism based on prion protein 
folding properties as an additional selective pressure against, particularly, Met129 
homozygosity. 
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Figure legends 
 
Fig. 1. Rapid refolding of recHuPrP90-231 with C-terminal His-tag from 
denatured/unfolded state by SEC-HPLC under conditions that favoured oligomers 
formation. (A) recHuPrP90-231 Met129, (B) recHuPrP90-231 Val129 and (C) an 
equimolar mixture (1:1) of Met129 and Val129 in 6 M guanidine hydrochloride, 50 
mM Tris-HCl pH 7.2 at 30 mg/ml were injected onto SEC and eluted with the 
equilibration buffer (20 mM sodium acetate, 0.2 M NaCl pH 3.7, 1 M urea and 0.02 
% sodium azide). (D) The areas under the peaks were analyzed using Total Chrome 
software 6.2 and the data used to construct the plot allowing a direct comparison of 10 
the proportions of the peaks eluted from SEC between Met129 and Val129 variants. 
 
Fig. 2. SEC profiles of fractions of recHuPrP90-231 during time course refolding into 
oligomer isoforms using dialysis method. (A) and (B) are chromatograms of 
recHuPrP90-231 Met129 and Val129 at 30 mg/ml and 10 mg/ml, respectively. Proteins 
in 6 M guanidine hydrochloride, 50 mM Tris-HCl pH 7.2 were dialyzed against 20 
mM sodium acetate, 0.2 M NaCl pH 3.7, 2 M urea and aliquots were withdrawn from 
the dialysis cassette at the indicated time then injected onto SEC previously 
equilibrated in 20 mM sodium acetate, 0.2 M NaCl pH 3.7, 1 M urea, 0.02% sodium 
azide. (C) and (D) are CD spectra of Met129 and Val129, respectively, recorded at 20 
the indicated times after manual collection of the oligomer fraction that eluted in peak 
(II) from samples in panel (A). 
 
Fig. 3. Time course analysis by RP-HPLC of oligomeric recHuPrP90-231. Aliquots of 
(A) recHuPrP90-231 Met129 and (B) recHuPrP90-231 Val129 that were refolded by 
dialysis into oligomer isoforms for 4 hours then fractionated by SEC (see panel A, 
Fig. 2) were incubated at room temperature in SEC elution buffer (20 mM sodium 
acetate, 0.2 M NaCl pH 3.7, 1 M urea, 0.02% sodium azide) and anlalyzed by RP-C4 
at the indicated times. The elution was done with a linear gradient of H2O + 0.1% 
TFA to 95 % acetonitrile + 0.09% TFA over 25 minutes. For direct comparison of 30 
retention times, monomeric α-helical and denatured (6M guanidine hydrochloride) 
PrPs were analyzed by RP-HPLC under the same conditions.  
 
 20
Fig. 4. Nanospray mass spectrometry analysis of peaks IIa and IIb after 12 days of 
oligomerization. Peak IIa and IIb that were resolved by HPLC-RPC4 during the 
oligomerization of Met129 and Val129 were manually collected and immediately 
subjected to mass spectrometry analysis. (A) and (B) are electrospray mass spectra 
and deconvoluted (see insets) mass spectra of peaks IIa and IIb, respectively, of 
Met129 oligomer. (C) and (D) are electrospray mass spectra and deconvoluted (see 
insets) mass spectra of peaks IIa and IIb, respectively, of Val129 oligomer. 
 
Fig. 5. Nanospray mass spectrometry and SDS-PAGE analysis of the proteinase K 
digests from oligomeric recHuPrP90-231. (A) Deconvoluted mass spectrum of 10 
polypeptides eluting at 23.35 minutes from C-18 reversed phase capillary HPLC (see 
inset) of Met129 oligomers. These correspond to residues 117-225 (12678 Da), 117-
232 (13488 Da) and 117-244 (14840 Da). (B) Deconvoluted mass spectrum of 
polypeptides eluting at 22.90 minutes (see inset) of Val129 oligomers. These 
correspond to residues 117-225 (12 646 Da), 117-232 (13456 Da) and 117-244 
(14808 Da). (C) Deconvoluted mass spectrum of polypeptides eluting at 21.33 
minutes (see inset in panel A) of Met129 oligomers. These correspond to residues 
135-222 (10752 Da), 135-225 (11114 Da), 135-232 (11924 Da) and 135-244 (13276). 
(D) Deconvoluted mass spectrum of polypeptides eluted at 21.55 minutes (see inset in 
panel B) of Val129 oligomers. These correspond to residues 135-222 (10752 Da), 20 
135-225 (11114 Da), 135-232 (11924 Da) and 135-244 (13276 Da). (E) Coomassie-
stained SDS-PAGE of limited proteinase K digests from Met129 and Val129 after 2, 
12 and 140 days of oligomerization. The digestion was carried out at 37 °C at the 
indicated incubation times with a ratio 1:24 PK to protein. (F) The PK-resistant 
fragments that were identified by mass spectrometry are overlaid on the amino acid 
sequence of human PrP Met/Val129. The residues that were introduced into the 
recombinant HuPrP for cloning and purification purposes are indicated in green at the 
N-terminal and in blue at the C-terminal. 
 
Fig. 6. Schematic model illustrating in vitro formation and maturation of oligomer 30 
isoforms of recHuPrP90-231 Met129 and Val129. Under appropriate conditions (low 
pH and high protein concentration) the acquisition of non-native form can happen 
from either denatured, aggregated or native forms and involves two steps: a rapid 
oligomerization phase followed by a slow maturation phase characterized by a 
 21
structural rearrangement of the oligomers. The presence of a methionine at codon 129 
affects both the kinetics of oligomerization and those of the maturation phase. 
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Figure legends 
(Supporting information) 
 
 
Fig. 1. Characterization and purification of allelomorphs of cloned Human PrP90-231 
with C-terminal His-tag. (A) and (B) are regions of the ABI traces showing the 
polymorphism at codon 129 in methionine and valine variants of PrP, respectively. 
(C) Representative chromatogram showing the elution profile of recHuPrP (Met129) 
during Ni-NTA sepharose-FPLC purification. (D) Coomassie-blue stained 18% SDS-
PAGE of selected fractions illustrating the level of purity of recHuPrP achieved from 10 
the metal affinity purification. (E) Characterization of the redox state of both 
allelomorphs of recHuman PrP90-231 with C-terminal His-tag by reversed-phase 
HPLC. Aliquots from the pooled fractions P3 (see panel C) were run on analytical 
RP-C4 HPLC either before or after treatment with 100 mM DTT. One concludes from 
the retention time that both variants were fully oxidized after Ni-NTA sepharose-
FPLC purification. After treatment with DTT both proteins became reduced and 
opened therefore exposing more hydrophobic residues to interact with the C4-alkyl 
chain hence requiring higher percentage of organic solvent for their elution which 
resulted in a higher retention times.  
 20 
Fig. 2. Time course analysis of the aggregated and monomeric fractions from Met129 
and Val129 under oligomer promoting condtions by SEC and PK digestion. (A) and 
(B) are chromatograms showing comparative evolution between Met129 and Val129, 
respectively, of aggregated fractions. Similarly, (C) and (D) are chromatograms 
showing comparative evolution between Met129 and Val129, respectively, of 
monomeric fractions. The protein concentration in each fraction was adjusted to 1 
mg/ml and incubated in SEC elution buffer (20 mM sodium acetate, 0.2 M NaCl pH 
3.7, 1 M urea, 0.02% sodium azide) at room temperature. Frations of 100 µl were 
injected onto SEC at the indicated times. (E) and (F) are coomassie-stained SDS-
PAGE of proteinase K digests from Met129 and Val129 after 0.04 (1 hour), 6 and 30 30 
days of oligomerization. The digestion was carried out at 37 °C at the indicated 
incubation times with a ratio of 1:24 (PK to protein). 
 
Fig. 3. Electrospray mass spectra and deconvoluted mass spectra of Met129 and 
Val129 allelomorphs over time during oligomerization. Because of the long storage 
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time of both allelomorphs in size exclution chromatography elution buffer (20 mM 
sodium acetate, 0.2 M NaCl, pH 3.7, 1 M urea and 0.02% sodium azide) at room 
temperature, we have used mass spectrometry to assess the integrity of the samples. 
After 2 days of oligomerization, both allelomorphs had molecular masses that 
matched the theoretical ones. However, after 30 days of oligomerization the 
deconvoluted mass spectra of both variants showed an additional species with a 
molecular mass that corresponded to the cleavage of two residues from the N-terminal 
part of the proteins. The two allelomorphs showed the same level of cleavage that 
seemed to continue over time to yield, 300 days later, proteins that were completely 
lacking two residues from the N-terminus. The amino acid sequence of cloned human 10 
PrP showed that the cleavage occurred in the peptide bond linking aspartyl residue to 
prolyl residue. The lability of Asp-Pro bonds has been reported before and therefore 
provides a simple explanation for our observation in the context of acidic conditions 
used during the oligomerization. The observed cleavage occurred at the same rate and 
equally between Met129 and Val129 and at a region of the N-terminal that was PK 
sensitive, therefore it was unlikely to impact the observed oligomerization differences 
 
Fig. 4. Overlay of SEC profiles of methionine 129 and valine 129 of recHuPrP90-231 
under mild (1 M urea) and strong denaturing (6 M guanidine hydrochloride) 
conditions. (A) Met129 and Val129 PrP in 6 M guanidine hydrochloride, 50 mM Tris-20 
HCl pH 7.2 at 30 mg/ml were injected onto SEC previously equilibrated in 20 mM 
sodium acetate, 0.2 M NaCl pH 5.5, 1 M urea and 0.02 % sodium azide, then eluted 
with the same buffer (B) Met129 and Val129 PrP in 6 M guanidine hydrochloride, 50 
mM Tris-HCl pH 7.2 at 30 mg/ml were injected onto SEC previously equilibrated in 6 
M guanidine hydrochloride, 50 mM Tris-HCl pH 7.2, then eluted with the same 
buffer. The injected volumes were 100 µl. Under both conditions the chromatograms 
revealed the presence of only monomeric species that eluted approximately at 9 
minutes, thus excluding the possibility of the pre-existing oligomeric specices in 6 M 
guanidine hydrochloride, 50 mM Tris-HCl pH 7.2 buffer. 
 30 
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